印度的Poviztra重量大药价格下降了多达55%. Emcure cuts Poviztra weight drug prices by up to 55% in India.

艾姆奎尔制药公司已将其减肥药Poviztra在印度的价格降低了高达55%,自2026年4月3日起生效. Emcure Pharmaceuticals has cut the price of its weight management drug Poviztra by up to 55% in India, effective April 3, 2026. 现在每月的初始剂量费用为3,999卢比, 从8,790卢比降低了. 高剂量的平均折扣率是47%. The starting dose will now cost Rs 3,999 per month, down from Rs 8,790, with higher doses seeing an average reduction of 47%. 印度的肥胖问题也在不断加剧, 但此举是由于新诺迪斯克公司最近降价并将产品专利到期而采取. This move follows the patent expiry of semaglutide and recent price cuts by Novo Nordisk, aiming to improve access amid India's growing obesity crisis.